These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1992598)

  • 1. Pharmacokinetics and metabolism of nilutamide.
    Creaven PJ; Pendyala L; Tremblay D
    Urology; 1991; 37(2 Suppl):13-9. PubMed ID: 1992598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate.
    Pendyala L; Creaven PJ; Huben R; Tremblay D; Bertagna C
    Cancer Chemother Pharmacol; 1988; 22(1):69-76. PubMed ID: 3396147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of nilutamide in the isolated rat lung.
    Camus P; Coudert B; D'Athis P; Foucher P; Delchambre J; Dupront A; Jeannin L
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1247-55. PubMed ID: 1762072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of nilutamide in rat lung.
    Ask K; Décologne N; Ginies C; Låg M; Boucher JL; Holme JA; Pelczar H; Camus P
    Biochem Pharmacol; 2006 Jan; 71(3):377-85. PubMed ID: 16313887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen.
    Berger V; Berson A; Wolf C; Chachaty C; Fau D; Fromenty B; Pessayre D
    Biochem Pharmacol; 1992 Feb; 43(3):654-7. PubMed ID: 1311586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of nilutamide.
    Gaillard-Moguilewsky M; de Gery A; Ulmann A
    Cancer; 1993 Dec; 72(12 Suppl):3828-9. PubMed ID: 8252498
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug.
    Ask K; Dijols S; Giroud C; Casse L; Frapart YM; Sari MA; Kim KS; Stuehr DJ; Mansuy D; Camus P; Boucher JL
    Chem Res Toxicol; 2003 Dec; 16(12):1547-54. PubMed ID: 14680368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide.
    Berson A; Wolf C; Berger V; Fau D; Chachaty C; Fromenty B; Pessayre D
    J Pharmacol Exp Ther; 1991 May; 257(2):714-9. PubMed ID: 1851835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilutamide pneumonitis: a report on eight patients.
    Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
    Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
    Fiet J; Doré JC; Gô AL; Ojasoo T; Raynaud JP
    Prostate; 1993; 23(4):291-313. PubMed ID: 8259343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.
    Setnikar I; Rovati LC
    Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeys.
    Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
    Arzneimittelforschung; 1992 Apr; 42(4):499-506. PubMed ID: 1642673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man.
    Jezequel SG; Uden S; Wastall P
    Xenobiotica; 1996 Sep; 26(9):963-75. PubMed ID: 8893043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
    Du Plessis DJ
    Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.